Aligos Therapeutics earnings were -$76.0M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest ALGS earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$1.5M, down 93.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ALGS reported annual earnings of -$24.2M, with -81.6% growth. The next ALGS earnings date is Nov 5, 2026.
Aligos Therapeutics Earnings Reports & History FAQ
What were Aligos Therapeutics's earnings last quarter?
On ALGS's earnings call on Aug 6, 2026, Aligos Therapeutics (NASDAQ: ALGS) reported Q2 2026 earnings per share (EPS) of -$0.14, up 90.85% year over year. Total ALGS earnings for the quarter were -$1.50 million. In the same quarter last year, Aligos Therapeutics's earnings per share (EPS) was -$1.53.
The next ALGS earnings date is Nov 5, 2026. Add ALGS to your watchlist to be reminded of Aligos Therapeutics's next earnings date.
Is Aligos Therapeutics profitable or losing money?
As of the last Aligos Therapeutics earnings report, Aligos Therapeutics is currently losing money. Aligos Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$75.96 million, a 2.4% increase year over year.
What was ALGS's earnings growth in the past year?
As of Aligos Therapeutics's earnings date in Aug 6, 2026, Aligos Therapeutics's earnings has grown year over year. ALGS earnings in the past year totalled -$75.96 million.
What are Aligos Therapeutics's earnings expectations?
The current EPS estimate for Aligos Therapeutics's earnings report in Nov 5, 2026 is -$2.43.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.